|
Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View
STATEMENT OF NEED
Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ... |
|
|
LET'S TALK: Tackling Complex Issues Regarding SM-AHN Management A Monday Morning Joe Online Educational Activity
Systemic mastocytosis (SM) is a group of rare disorders characterized by the accumulation of mast cells in internal tissues and organs. The pathogenesis of SM is linked to a characteristic exon 17 D816V mutation of the KIT gene. Systemic mastocytosis with associated hematologic neoplasms (SM-AHN) is an advanced subtype of SM that is associated with a shortened median survival time. Recent advances in the SM therapeutic landscape have led to the development of KIT-targeted treatment options; ho... |
|
|
The Immune Reconstitution Syndrome in AIDS
This course addresses the complexities of HIV disease in the era of improved survival: recognition and management of the immune reconstitution syndrome.
Outcome Objectives:
As a result of completing this activity, the participant will be better able to:
- Recognize that restoration of immunologic function in persons with HIV disease may lead to a worsening clinical picture, the immune reconstitution syndrome.
- Diagnose and manage occult opportunistic infections in persons with newly... |
|
|
Treating Hepatitis C in Patients with HIV Disease
This course addresses the complexities of HIV disease in the era of improved survival: management of HIV co-infection.
Outcome Objectives:
As a result of completing this activity, the participant will be better able to:
- Diagnose the clinical syndrome of porphyria cutanea tarda.
- Diagnose hepatitis C.
- Adjust the treatment of hepatitis C based on viral genotype and liver pathology. |
|